Develops therapies for oncology and neurology, focusing on repurposing existing drugs for new therapeutic indications.
Kintara Therapeutics, Inc., a clinical-stage biopharmaceutical company, is dedicated to advancing innovative anti-cancer therapies for patients battling various forms of cancer. Central to its mission are two Phase III-ready therapeutics poised to address critical unmet needs in oncology. One of these is VAL-083, a potent DNA-targeting agent designed to combat drug-resistant solid tumors, including glioblastoma multiforme, ovarian cancer, non-small cell lung cancer, and diffuse intrinsic pontine glioma. The company also focuses on REM-001, an advanced photodynamic therapy intended for treating cutaneous metastatic breast cancer, basal cell carcinoma nevus syndrome, and addressing graft failure in hemodialysis patients.
In pursuit of its therapeutic goals, Kintara Therapeutics benefits from strategic collaborations, such as its partnership with Guangxi Wuzhou Pharmaceutical (Group) Co. Ltd., aimed at manufacturing and distributing VAL-083 within China. Founded in 2009 and originally known as DelMar Pharmaceuticals, Inc., the company rebranded as Kintara Therapeutics, Inc. in August 2020 to better reflect its expanded focus and strategic direction. Headquartered in San Diego, California, Kintara Therapeutics continues to drive forward with a commitment to pioneering oncological treatments that improve outcomes and quality of life for cancer patients worldwide.